ClinicoEconomics and Outcomes Research (Mar 2022)

Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System

  • Torres A,
  • Soriano A,
  • Rivolo S,
  • Remak E,
  • Peral C,
  • Kantecki M,
  • Ansari W,
  • Charbonneau C,
  • Hammond J,
  • Grau S,
  • Wilcox M

Journal volume & issue
Vol. Volume 14
pp. 149 – 161

Abstract

Read online

Antoni Torres,1 Alex Soriano,2 Simone Rivolo,3 Edit Remak,4 Carmen Peral,5 Michal Kantecki,6 Wajeeha Ansari,7 Claudie Charbonneau,8 Jennifer Hammond,9 Santiago Grau,10 Mark Wilcox11 1Servei de Pneumologia Hospital Clinic, University of Barcelona, IDIPAPS, CIBERES, ICREA, Barcelona, Spain; 2Hospital Clínic of Barcelona,University of Barcelona, IDIBAPS, Barcelona, Spain; 3Modeling and Simulation, Evidera, London, UK; 4Formerly Modeling and Simulation, Evidera, Budapest, Hungary; 5Health Economics and Outcomes Research, Pfizer, Madrid, Spain; 6Global Medical Affairs, Pfizer, Paris, France; 7Patient & Health Impact, Pfizer, New York, NY, USA; 8Patient & Health Impact, Pfizer, Paris, France; 9Global Product Development, Pfizer, Collegeville, PA, USA; 10Hospital del Mar,Universitat Pompeu Fabra, Barcelona, Spain; 11University of Leeds, Leeds, UKCorrespondence: Wajeeha Ansari, Tel +1 212 733 5001, Email [email protected]: Complicated skin and soft tissue infections (cSSTI) are associated with high healthcare resource use and costs. The emergency nature of cSSTI hospitalizations requires starting immediate empiric intravenous (IV) antibiotic treatment, making the appropriate choice of initial antibiotic therapy crucial.Patients and Methods: The use of ceftaroline fosamil (CFT) as an alternative to other IV antibiotic therapies for the empiric treatment of hospitalized adults with cSSTI (vancomycin, linezolid, daptomycin, cloxacillin, tedizolid) was evaluated through cost consequences analysis. The model structure was a decision tree accounting for four different pathways: patients demonstrating early response (ER) either discharged early (with oral antibiotic) or remaining in hospital to continue the initial therapy; non-responders either remaining on the initial IV therapy or switching to a second-line antibiotic. The model perspective was the Spanish National Health System.Results: CFT resulted in average percentage of patients discharged early (PDE) of 24.6% (CI 19.49– 30.2%) with average total cost per patient of € 6763 (€ 6268–€ 7219). Vancomycin, linezolid, daptomycin and tedizolid resulted in average PDE of 22% (17.34– 27.09%), 26.4% (20.5– 32.32%), 28.6% (22.08– 35.79%) and 26.5% (20.39– 33.25%), respectively, for a total cost per patient of € 6,619 (€ 5,902–€ 6,929), € 6,394 (€ 5,881–€ 6,904), € 6,855 (€ 5,800–€ 7,410) and € 7,173 (€ 6,608–€ 7,763), respectively. Key model drivers were ER and antibiotic treatment duration, with hospital costs accounting for over 83% of the total expenditures.Conclusion: Given its clinical and safety profile, CFT is an acceptable choice for cSSTI empiric therapy providing comparable ER and costs to other relevant antibiotic options.Keywords: complicated skin and soft tissue infection, cost-consequences, Spain, ceftaroline fosamil

Keywords